Bausch + Lomb Co. (NYSE:BLCO) Receives Consensus Recommendation of "Hold" from Analysts

Shares of Bausch + Lomb Co. (NYSE:BLCO - Get Free Report) have been assigned an average recommendation of "Hold" from the twelve brokerages that are currently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $20.82.

Several equities analysts have recently weighed in on the stock. HC Wainwright raised their price target on shares of Bausch + Lomb from $22.00 to $23.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Wells Fargo & Company boosted their target price on Bausch + Lomb from $23.00 to $26.00 and gave the stock an "overweight" rating in a report on Thursday, October 31st. Evercore ISI upgraded Bausch + Lomb from an "in-line" rating to an "outperform" rating and upped their price target for the company from $19.00 to $25.00 in a research report on Tuesday, October 15th. Stifel Nicolaus lifted their price objective on Bausch + Lomb from $16.00 to $19.00 and gave the stock a "hold" rating in a research report on Monday, September 23rd. Finally, Needham & Company LLC reissued a "hold" rating on shares of Bausch + Lomb in a research note on Thursday, October 31st.

Institutional Trading of Bausch + Lomb

Institutional investors have recently added to or reduced their stakes in the stock. River Road Asset Management LLC boosted its stake in shares of Bausch + Lomb by 4.4% in the third quarter. River Road Asset Management LLC now owns 2,020,414 shares of the company's stock valued at $38,974,000 after purchasing an additional 85,987 shares during the period. Whitebox Advisors LLC increased its position in shares of Bausch + Lomb by 28.2% during the second quarter. Whitebox Advisors LLC now owns 1,545,946 shares of the company's stock worth $22,447,000 after acquiring an additional 339,643 shares during the period. King Street Capital Management L.P. purchased a new position in Bausch + Lomb in the third quarter valued at $14,122,000. Clearline Capital LP grew its stake in Bausch + Lomb by 136.8% during the 2nd quarter. Clearline Capital LP now owns 712,055 shares of the company's stock worth $10,339,000 after purchasing an additional 411,404 shares in the last quarter. Finally, Point72 Europe London LLP raised its position in Bausch + Lomb by 28.9% in the 2nd quarter. Point72 Europe London LLP now owns 653,492 shares of the company's stock valued at $9,489,000 after purchasing an additional 146,583 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company's stock.

Bausch + Lomb Price Performance

Bausch + Lomb stock traded down $2.49 during midday trading on Wednesday, reaching $18.16. The company had a trading volume of 3,074,311 shares, compared to its average volume of 559,676. Bausch + Lomb has a 12-month low of $13.16 and a 12-month high of $21.69. The firm's fifty day simple moving average is $19.89 and its 200-day simple moving average is $17.47. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.57 and a quick ratio of 0.95. The company has a market capitalization of $6.40 billion, a P/E ratio of -17.30, a P/E/G ratio of 1.93 and a beta of 0.43.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.01. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. The firm had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company posted $0.22 earnings per share. The business's revenue was up 18.8% on a year-over-year basis. As a group, equities analysts anticipate that Bausch + Lomb will post 0.6 EPS for the current year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.